Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

NFX 179

X
Drug Profile

NFX 179

Alternative Names: NFX-179

Latest Information Update: 07 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator NFlection Therapeutics
  • Class Antineoplastics; Chemopreventatives; Skin disorder therapies; Small molecules
  • Mechanism of Action Mitogen-activated protein kinase kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Neurofibromatosis 1
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Neurofibromatosis 1
  • Preclinical Skin disorders; Squamous cell cancer

Most Recent Events

  • 23 May 2024 NFlection Therapeutics withdraws prior to enrollment a phase II trial in Nevus because sponsor declined to proceed (NCT05195762)
  • 13 Nov 2023 NFX 179 receives Orphan Drug status for Neurofibromatosis 1 in European Union, prior to November 2023
  • 13 Nov 2023 Efficacy, pharmacokinetics and adverse events data from a phase IIb trial for Neurofibromatosis type 1 released by NFlection Therapeutics

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top